FDA Patent Listing Procedures May Need Revision, Hatch And Waxman Say

FDA should apply more judgment in analyzing patents submitted for listing in the "Orange Book" when generic competition is imminent, Sens. Kennedy (D-Mass.) and Hatch (R-Utah) and Rep. Waxman (D-Calif.) said in a letter to HHS Secretary Thompson.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet